CD103+ DCs, presenting tumour antigen in the TDLN were able to promote tumour specific antigen mediated T cell activation and proliferation. Expansion of CD103+ DCs following poly I:C administration enhanced tumour response to BRAF or PD-L1 blockade. Here, BRAF is linked to neoplasm.